RodanG.A., FleischH.A.: Bisphosphonates: mechanisms of action.J Clin Invest,97: 2692, 1996.
2.
RuggieroS.L., MehrotraB., RosenbergT.J., EngroffS.L.: Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.J Oral Maxillofac Surg, 62: 527–534, 2004.
3.
MiglioratiC.A.: Bisphosphonates and oral cavity avascular bone necrosis.J Clin Oncol, 21: 4253–4254, 2003.
4.
SannaG., ZampinoM.G., PelosiG., NolèF., GoldhirschA.: Jaw avascular bone necrosis associated with long-term use of bisphosphonates.Ann Oncol, 16: 1207–1208, 2005.
5.
MarxR.E.: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.J Oral Maxillofac Surg, 61: 1115–1117, 2003.
6.
FournierP., BoissierS., FilleurS.: Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular re-growth in the ventral prostate in castrated rats.Cancer Res, 15: 6538–6544, 2002.
